CompletedPhase 2

Impact of Perioperative Levosimendan on Patients Undergoing Cardiac Surgery With Low Ejection Fraction

Egypt240 participantsStarted 2021-01-01

Plain-language summary

to compar levosemindan to other cardiac intropic medications that strengthen the heart in diffrent common adult heart surgery with patients with low ejection fraction(weak heart)

Who can participate

Age range20 Years – 70 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Valve surgery
✓. CABG surgery,
✓. combined surgery
✓. all patients Ejection Fraction less than 35 ٪ -

Exclusion criteria

✕. Patients age ≤ 20-70 \< years
✕. Aortic and redo surgery
✕. any patients with Ejection Fraction more than 35 ٪ -

What they're measuring

death through day 30,

Timeframe: 1 month (no scale for measurement as death may occured due to multible causes that be difficult to be identified and measured )

Renal-replacement therapy

Timeframe: 1 month

Perioperative myocardial infarction

Timeframe: 5 days

Intra Aortic Ballon Pumb insertion

Timeframe: 5 days(no scale for measurement )

Trial details

NCT IDNCT06784570

SponsorZagazig University

Sponsor typeOTHER_GOV

Study typeINTERVENTIONAL

Primary completion2024-03-01

View on ClinicalTrials.gov More Cardiac Surgery trials